Richard Aranda
Chief Tech/Sci/R&D Officer chez GOSSAMER BIO, INC.
Fortune : 234 583 $ au 31/03/2024
Postes actifs de Richard Aranda
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GOSSAMER BIO, INC. | Chief Tech/Sci/R&D Officer | 01/06/2021 | - |
| Corporate Officer/Principal | - | 01/06/2021 |
Historique de carrière de Richard Aranda
Anciens postes connus de Richard Aranda
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| RECEPTOS INC | Corporate Officer/Principal | 01/01/2015 | 01/01/2018 |
| Novo-Nordisk Biochem, Inc. | Corporate Officer/Principal | 01/01/2011 | 01/01/2015 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/08/2001 | 01/05/2011 |
Formation de Richard Aranda
| University of California, Santa Cruz | Undergraduate Degree |
| Stanford School of Medicine | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| Corporate Officer/Principal | 4 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
| Novo-Nordisk Biochem, Inc. |
- Bourse
- Insiders
- Richard Aranda
- Expérience
